



GNA NOW SYMPOSIUM

Next Steps in Enteric Antibacterial Development: Evidence, Gaps & Actions

AGENDA

22 September 2026

11:00 - 12:00

- Welcome (Kristina Orrling, GNA NOW coordinator, Lygature)
- Target Product Profile update (Alasdair MacGowan, North Bristol Trust)
- Correlations between *in vitro* and *in vivo* preclinical enteric disease models (Shampa Das, University of Liverpool)
- Panel discussion:
 - How to further incentivise the development of new antibiotics for severe enteric disease
 - What data and knowledge gaps are most urgent to address

PANELLISTS

- Samuel Mungai Kariuki, DNDi, Kenya
- Sumathi Nambiar, Johnson & Johnson
- David Paterson, Saw Swee Hock School of Public Health, Singapore
- Alasdair MacGowan, North Bristol Trust
- Shampa Das, University of Liverpool

Chair: Richard Alm, CARB-X



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853979: 'GNA NOW: Gram-Negative Antibacterials NOW'. The JU receives support from the European Union's Horizon 2020 research and innovation programme and is part of the AMR Accelerator.

